NSAID PREPARATIONS. COMPOSITION : Each enteric coated tablet contains Diclofenac Sodium BP 25 mg. Clofenac 50. Clofenac SR. Sodium BP 50 mg.



Similar documents
patient group direction

UpRight Aceclofenac 100 mg and Paracetamol 500 mg fixed dose combination

There is a risk of renal impairment in dehydrated children and adolescents.

Ibuprofen 10% w/w gel Nurofen Maximum Strength 10 % Gel

PACKAGE INSERT TEMPLATE FOR ACETYLSALICYLIC ACID/ASPIRIN TABLET

Doxylamine succinate belongs to the ethanolamine class of antihistamines with sedative properties.

PARACETAMOL REXIDOL. 600 mg Tablet. Analgesic-Antipyretic. Paracetamol 600 mg

PACKAGE LEAFLET. CLINDAMYCIN capsules Clidamycin. One capsule of 75 mg contains 75 mg Clindamycin (as hydrochloride).

VOLTAROL Suppositories 12.5, 25, 50 and 100 mg (diclofenac sodium)

VISTARIL (hydroxyzine pamoate) Capsules and Oral Suspension

PHOSPHATE-SANDOZ Tablets (High dose phosphate supplement)

EFFIMET 1000 XR Metformin Hydrochloride extended release tablet

White, circular, biconvex, uncoated tablets with a score line on one side, plain on the other.

ZOVIRAX Cold Sore Cream

Influence of ph Most local anesthetics are weak bases.

Essential Shared Care Agreement Drugs for Dementia

PRODUCT INFORMATION PANAMAX

Review of Pharmacological Pain Management

PATIENT INFORMATION LEAFLET. CEFALEXIN 250 mg AND 500 mg CAPSULES CEFALEXIN

Nursing 113. Pharmacology Principles

Psoriasis and Psoriatic Arthritis Alliance

SR 5. W2364A_NT.XATRAL SR5 PAK/SA 5/12/05 9:47 Page 1

PATIENT INFORMATION LEAFLET Phor Migraine (Ibuprofen)

Always take this medicine exactly as described in this leaflet or as your doctor, pharmacist or nurse have told you.

COMPOSITION: Each capsule contains clindamycin hydrochloride equivalent to 150 mg clindamycin base.

LEFLUNOMIDE (Adults)

See 17 for PATIENT COUNSELING INFORMATION. Revised: 3/2016 FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: ADRENAL CRISIS IN THE SETTING OF SHOCK OR

NIMULID MD. 1. Introduction. 2. Nimulid MD Drug delivery system

Adjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.

P AC K AG E L E AF L E T: INFORMAT I ON FO R THE USER. 500 mg, film-coated tablet Active substance: metformin hydrochloride

Elderly: in elderly patients there is no need to reduce the daily dosage (see section 5.2).

Calcium Folinate Ebewe Data Sheet

Thioctacid 600 T Solution for Injection contains 600 mg alpha-lipoic acid

Package leaflet: Information for the user. < ASPROFLASH and associated names > 500 mg coated tablet Acetylsalicylic acid

EMEA PUBLIC STATEMENT ON LEFLUNOMIDE (ARAVA) - SEVERE AND SERIOUS HEPATIC REACTIONS -

Nonsteroidal. Drugs (NSAIDs) Anti-Inflammatory. North American Spine Society Public Education Series

Nurse Initiated Medications Procedure

DICLOFENAC POTASSIUM 12.5 MG TABLETS PL 24668/0001 UKPAR TABLE OF CONTENTS

Nōdia DESCRIPTION PHARMACOLOGY. Loperamide hydrochloride USP 2 mg Tablets. Pharmacological classification - antidiarrhoeal.

4 Clinical Particulars

New Zealand Data Sheet

This leaflet answers some common questions about ARROW - MELOXICAM.

Elements for a public summary. VI.2.1 Overview of disease epidemiology. VI.2.2 Summary of treatment benefits

Paracetamol apollo Paracetamol apollo Paracetamol

DATA SHEET. This product is may not be interchangeable with other products containing this ingredient in the New Zealand Market.

PACKAGE LEAFLET: INFORMATION FOR THE USER Omeprazol XXX 40 mg powder for solution for infusion omeprazole

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Medications for chronic pain

ENZAR FORTE TABLETS. (derived from Pancreatin USP) Sodium tauroglycocholate BPC 65mg (with sugar coating containing essential carminative oils)

3% Sodium Chloride Injection, USP 5% Sodium Chloride Injection, USP

SYNACTHEN i.m./i.v. tetracosactide hexaacetate

Stowe School Medications Policy

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only OR for Specialist Use only

PACKAGE LEAFLET: INFORMATION FOR THE USER Paracetamol 500 mg Effervescent Tablets Paracetamol

Public Assessment Report

SUMMARY OF PRODUCT CHARACTERISTICS

PACKAGE LEAFLET: INFORMATION FOR THE USER. PARACETAMOL MACOPHARMA 10 mg/ml, solution for infusion. Paracetamol

Topical Tacrolimus or Pimecrolimus for the treatment of mild, moderate or severe atopic eczema. Effective Shared Care Agreement

SYNACTHEN DEPOT i.m. (tetracosactide hexaacetate) 1 mg/ml Suspension for injection

Ask Your Doctor if There May Be a SMARTER CHOICE

Data Sheet. Paraldehyde

Arthritis and Rheumatology Clinics of Kansas Patient Education. Reactive Arthritis (ReA) / Inflammatory Bowel Disease (IBD) Arthritis

Over the Counter Drugs (OTCs): Considerations for Physical Therapy Practice in Canada

It can therefore be bought without a prescription but should be used correctly to ensure its efficacy and to reduce side effects.

SUMMARY OF PRODUCT CHARACTERISTICS BREXIN. 3. Pharmaceutical Form Tablet Pale yellow, hexagonal tablet with a median score line on one side

DIVISION OF RHEUMATOLOGY DEPARTMENT OF MEDICINE UNIVERSITY OF WESTERN ONTARIO POSTGRADUATE EDUCTION ORTHOPAEDIC OFF-SERVICE GOALS & OBJECTIVES

Rheumatoid Arthritis monitoring of DMARDs

Safety Information Card for Xarelto Patients

DULCOLAX Tablets and Suppositories Bisacodyl

Intestinal Permeability Leaky Gut Syndrome Protocol Dr. Kurt Woeller, D.O.

Arthritis of the Shoulder

Teriflunomide is the active metabolite of Leflunomide, a drug employed since 1994 for the treatment of rheumatoid arthritis (Baselt, 2011).

Glycopyrronium Bromide 0.5mg/mL and Neostigmine Metilsulfate 2.5mg/mL Solution for Injection

CONSENT FOR STEROID INJECTION

**Form 1: - Consultant Copy** Telephone Number: Fax Number: Author: Dr Bernard Udeze Pharmacist: Claire Ault Date of issue July 2011

The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in May 2013.

Shared Care Guideline for the use of Leflunomide for Rheumatoid Arthritis

2 What you need to know before you have Ampiclox

Perfalgan 10 mg/ml, solution for infusion

Biologic Treatments for Rheumatoid Arthritis

Yes This controlled document shall not be copied in part or whole without the express permission of the author or the author s representative.

PHENYLEPHRINE HYDROCHLORIDE INJECTION USP

Methotrexate Dose For Juvenile Rheumatoid Arthritis

PACKAGE LEAFLET: INFORMATION FOR THE USER. ADRENALINE (TARTRATE) STEROP 1 mg/1 ml Solution for injection. Adrenaline (Levorenine, Epinephrine)

Package leaflet: Information for the patient. Laxido Orange, powder for oral solution

Amylase and Lipase Tests

IBUPROFEN 400MG TABLETS PL 20395/0080 UKPAR TABLE OF CONTENTS

SUMMARY OF THE RISK MANAGEMENT PLAN (by medicinal product)

SUMMARY OF PRODUCT CHARACTERISTICS. Paracetamol mg for 1 ml of solution for infusion

Single Blind, Comparative Study of Ketoprofen Cream Vs Diclofenac and Piroxicam Cream in Management of Rheumatoid Arthritis Patients

VOLTAREN OPHTHA EYE DROPS

Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF

Public Assessment Report. Table of Contents

I B2.4. Design of the patient information leaflet for VariQuin

Before you use Voltaren. When you must not use it

GLUCOSAMINE, CHONDROITIN, AND MSM

Allopurinol Allopurinol

PACKAGE LEAFLET: INFORMATION FOR THE USER. ADRENALINE (HCl) STEROP 0,8mg/1ml. Solution for injection. Adrenaline (Levorenine, Epinephrine)

Patient Group Direction Hospital: Bristol Royal Infirmary Department: UHBristol Thrombosis Service University Hospitals Bristol NHS Foundation Trust.

Hand Injuries and Disorders

Transcription:

Diclofenac Analgesic & Anti-inflammatory COMPOSITION Clofenac 25 : Each enteric coated tablet contains Diclofenac Sodium BP 25 mg. Clofenac 50 : Each enteric coated tablet contains Diclofenac Sodium BP 50 mg. Clofenac SR : Each enteric coated tablet contains Diclofenac Sodium BP 100 mg in a sustained release formulation. Clofenac injection : Each 3 ml ampoule contains Diclofenac Sodium BP 75 mg. Clofenac Plus injection : Each 2 ml ampoule contains Diclofenac Sodium BP 75 mg and Lidocaine Hydrochloride USP 20 mg. Clofenac Gel : Each 100 gm gel contains 1.16 gm Diclofenac Diethyl ammonium salt which corresponds to 1 gm Diclofenac Sodium BP. Clofenac 12.5 Suppository : Each suppository contains Diclofenac Sodium BP 12.5 mg. Clofenac 50 Suppository : Each suppository contains Diclofenac Sodium BP 50 mg. PHARMACOLOGY Clofenac contains Diclofenac, which is a potent non-steroidal antiinflammatory drug (NSAID) with marked analgesic and antipyretic properties. It also has some uricosuric effect. The actions of diclofenac appear to be associated principally with the inhibition of prostaglandin synthesis - by inhibiting cyclooxygenase - the enzyme that catalyzes the formation of prostaglandin precursors (endoperoxides) from arachidonic acid. Following oral administration, diclofenac is rapidly absorbed from the gastro-intestinal tract. Peak plasma concentration following ingestion of an enteric coated tablet occurs at about 2 to 3 hours and that following injection occurs within half an hour. Diclofenac is 99.7% bound to plasma proteins and plasma half-life for the terminal elimination phase is 1-2 hours. Diclofenac enters the synovial fluid, where maximum concentrations are measured 2-4 hours after the peak plasma values have been obtained. The apparent half-life for elimination from the synovial fluid is 3-6 hours. Diclofenac is extensively metabolized to

a range of phenolic compounds. About 60% of the administered dose is excreted via the kidneys in the form of metabolites and less than 1% in unchanged form. The remainder is excreted via the bile in metabolised form. Clofenac Plus Injection contains Diclofenac Sodium BP and Lidocaine Hydrochloride USP. Lidocaine is the most widely used local anaesthetic drug. It acts more rapidly and is more stable than most other local anaesthetics. It is a very useful surface anaesthetic. Like other local anaesthetic, lidocaine impairs the generation and conduction of the nerve impulses by slowing depolarization. The onset of anaesthesia of lidocaine HCl is more rapid and the duration of action is longer. A 1%-2% solution has a duration of action of about 1-2 hours. Binding of lidocaine to plasma proteins is variable and concentration dependent. Approximately 90% of a parenteral dose of lidocaine is rapidly metabolized in the liver. Less than 10% of a dose is excreted unchanged in the urine. Clofenac Gel contains diclofenac sodium BP 1% as diclofenac diethyl ammonium salt. It has been designed for external use. The white creamy non-greasy preparation can easily be rubbed into the skin and its aqueous alcoholic base exerts a soothing and cooling effect on the skin. After local application, the active substance penetrates the skin, accumulates in the underlying tissue and combats both acute and chronic inflammatory reaction. The anti-inflammatory and analgesic properties of Clofenac Gel elicits a clinical response characterized by a marked decrease in inflammatory swelling of traumatic or rheumatic origin. It affords effective relief from tenderness and pain on movement. INDICATION Clofenac tablets, Clofenac injection, Clofenac Plus injection and Clofenac suppositories contain diclofenac sodium, which is used to relief all grades of pain and inflammation in a wide range of conditions including: a) Arthritic conditions: Rheumatoid Arthritis, Osteoarthritis, Ankylosing spondylitis, Acute gout. b) acute musculoskeletal disorders such as periarthritis (e.g., frozen shoulder), tendinitis, tenosynovitis, bursitis. c) other painful conditions resulting from trauma, including fracture, low back pain, sprains, strains, dislocations, orthopaedic, dental and other minor surgery. Clofenac Plus injection also contains lidocaine, which acts as a local

anaesthetic. Therefore, the possibility of pain at the injection site, which is most likely to occur after intramuscular injection of normal diclofenac, is minimized if Clofenac Plus Injection is used. Clofenac Gel is used for the local symptomatic relief of pain and inflammation in: a) trauma of the tendons, ligaments, muscles and joints, e.g, due to sprains, strains and bruises, b) localised forms of soft tissue rheumatism. DOSAGE AND ADMINISTRATION Clofenac 25 mg and 50 mg enteric coated tablets : Adults: 75-150 mg daily in 2 to 3 divided doses, preferably after food. Dose should be reduced in long term use. Clofenac SR : 1 tablet daily, taken whole with liquid, preferably at meal times. If necessary, the daily dose can be increased to 150 mg by supplementation with conventional tablets. Children: 1-3 mg of diclofenac/kg body wt. daily in divided doses. Elderly patients: In elderly or debilitated patients, the lowest effective dosage is recommended, although the pharmacokinetics of diclofenac sodium are not impaired to any clinically relevant extent in elderly patients. Clofenac injection/clofenac Plus injection : Adults: One ampoule once (or in severe cases, twice) daily by intramuscular injection. Renal colic: One ampoule once daily intramuscularly. A further ampoule may be administered after 30 minutes, if necessary. The recommended maximum daily dose of diclofenac is 150 mg, by any route. The recommended maximum daily dose of lidocaine is 200 mg. Children: In juvenile chronic arthritis, 1-3 mg of diclofenac/kg body wt. daily in divided doses. Elderly patients: In elderly or debilitated patients, the lowest effective dosage is recommended, commensurate with age and physical status. Clofenac Gel : Clofenac Gel should be rubbed gently into the skin. Depending on the size of the affected site to be treated 2-4 gm Clofenac Gel should be applied 3-4 times daily and rubbed in lightly. After application, the hands should be washed unless they are the site being treated.

Use in the elderly: The usual adult dosage may be used. Clofenac Gel may also be given to further treatment with other dosage forms of Clofenac. or as prescribed by the physician. Clofenac Suppository : Suppository should be administered rectally. Adults: 50 mg suppository 2-3 times daily. Maximum daily dose is 150 mg. Children: 12.5 mg suppository 2-3 times daily, or 1-3 mg/kg per day in divided doses. CONTRAINDICATION AND PRECAUTION Diclofenac is contra-indicated for those patients who are hypersensitive to diclofenac. In patients with active or suspected peptic ulcer or gastrointestinal bleeding, or for those patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs possessing prostaglandin synthetase inhibiting activity, diclofenac is also contra-indicated. Because of the presence of lidocaine, Clofenac -Plus injection is also contra-indicated for those patients who are hypersensitive to local anaesthetics of the amide type, although the incidence is very rare. In patients with Adams-Stokes syndrome or with severe degrees of SA, AV, or intraventricular heart block in the absence of an artificial pacemaker, and for those patients who are hypersensitive to any of the excipients used in the formulation (sodium metabisulphite, mannitol, benzyl alcohol, propylene glycol), this injection is also contra-indicated. Clofenac Gel is also contra-indicated to those who are hypersensitive to the gel base. Renal: Patients with severe hepatic, cardiac or renal insufficiency or the elderly should be kept under close surveillance, since the use of NSAIDs may result in deterioration of renal function. The lowest effective dose should be used and renal function monitored. Hepatic: If abnormal liver function tests persist or worsen, clinical signs or symptoms consistent with liver disease develop or if other manifestations occur (eosinophilia, rash), diclofenac should be discontinued. All patients who are receiving long term treatment with NSAIDs should be monitored as a precautionary measure (e.g., renal, hepatic function and blood counts).

Clofenac Gel should not be taken by mouth and should not be used under occlusive, airtight dressings. The gel should not be allowed to come in contact with the eyes or mucous membranes. SIDE EFFECT Side effects to diclofenac are usually mild and transient. However, if serious side effects occur, diclofenac should be discontinued. Gastrointestinal: Occasional: epigastric pain, other gastro-intestinal disorders (e.g., nausea, vomiting, diarrhoea, abdominal cramps, dyspepsia, flatulence, anorexia). Rare: gastro-intestinal bleeding, peptic ulcer (with or without bleeding or perforation), bloody diarrhoea. In isolated cases: lower gut disorders (e.g., non-specific haemorrhagic colitis and exacerbations of ulcerative colitis or Crohn's proctocolitis), pancreatitis, glossitis,constipation, etc. Clofenac Plus injection: In very rare instances, injection site disorders may occur. In isolated cases, abscesses and local necrosis may occur. The adverse effects due to lidocaine mainly involve the CNS, are usually of short duration, and are dose related. The CNS reactions may be manifested by drowsiness, dizziness, disorientation, confusion, lightheadedness, etc. Clofenac Gel is usually well tolerated. Local irritation, erythema, pruritus or dermatitis may occasionally occur. Although the gel has low systemic absorption, yet the possibility of the systemic side-effects cannot be completely excluded because of use to a relatively large area of skin. DRUG INTERACTION Clofenac Gel: No drug interaction during treatment with diclofenac gel have been reported. All other dosage forms may have the following drug interactions : Lithium and digoxin: Diclofenac may increase plasma concentrations of lithium and digoxin. Anticoagulants: There are isolated reports of an increased risk of haemorrhage with the combined use of diclofenac and anticoagulant therapy, although clinical investigations do not appear to indicate any influence on anticoagulant effect. Antidiabetic agents: Clinical studies have shown that diclofenac can be given together with oral antidiabetic agents without influencing their clinical effect. Cyclosporin: Cases of nephrotoxicity have been reported in patients receiving cyclosporin and diclofenac concomitantly.

Methotrexate: Cases of serious toxicity have been reported when methotrexate and NSAIDs are given within 24 hours of each other. Quinolone antimicrobials: Convulsions may occur due to an interaction between quinolones and NSAIDs. Therefore, caution should be exercised when considering concomitant therapy of NSAID and quinolones. Other NSAIDs and steroids: Co-administration of diclofenac with other systemic NSAIDs and steroids may increase the frequency of unwanted effects. With aspirin, the plasma levels of each is lowered, although no clinical significance is known. Diuretics: Various NSAIDs areliable to inhibit the activity of diuretics. Concomitant treatment with potassium-sparing diuretics may be associated with increased serum potassium levels. So, serum potassium should be monitored. USE IN PREGNANCY AND LACTATION Diclofenac tablets and injection should not be prescribed during pregnancy, unless there are compelling reasons for doing so. The lowest effective dosage should be used. This type of drugs are not recommended during the last trimester of pregnancy. Very small quantities of diclofenac may be detected in breast milk, but no undesirable effects on the infant are to be expected. Since no experience has been acquired with diclofenac gel in pregnancy or lactation, it is not recommended for use in these circumstances. STORAGE CONDITION Protect from heat, light, and moisture. Clofenac Suppository: Store below 30 C. HOW SUPPLIED Clofenac 25 : Box containing 10 x 10 tablets in blister pack. Clofenac 50 : Box containing 20 x 10 tablets in blister pack. Clofenac SR : Box containing 10 x 10 tablets in blister pack. Clofenac injection : Box containing 5 x 2 ampoules of 3 ml in blister pack. Clofenac Plus injection : Box containing 2 x 5 ampoules of 2 ml in blister pack. Clofenac Gel 10 gm : Tube containing 10 gm gel. Clofenac 12.5 mg Suppository : Box containing 2 x 5 suppositories in blister pack. Clofenac 50 mg Suppository : Box containing 2 x 5 suppositories in blister pack.